CIK 0001228627
- Non-accelerated filer
- Smaller reporting company
Opus Genetics, Inc.
Sign in to watch- Ticker
- IRD
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 113516358
- Phone
- +1 984-884-6030
- Business address
- 8 DAVIS DRIVE, SUITE 220, DURHAM, NC, 27713
- Former names
- Ocuphire Pharma, Inc., REXAHN PHARMACEUTICALS, INC., CORPORATE ROAD SHOW DOT COM INC, FERRARO FRANK
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $3,211,769
- in 7 filings, $50K under 10b5-1 plans
Net −$3,211,769. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Foundation Fighting Blindness Retinal Degeneration Fund −$2.8M Director sold 15% of stake
- Gagnon Robert E. −$177K Chief Financial Officer sold 7% of stake
- Magrath George −$145K Chief Executive Officer sold 2% of stake
- YERXA BENJAMIN R −$117K President sold 5% of stake
- SCHACHLE JOSEPH K −$17K Chief Operating Officer sold 2% of stake
Reading 46 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2014-04-14 | McIntosh David M Director | Shares withheld for taxes | −99,010 | $1.01 | $100K | 25,990 |
| 2014-04-14 | McIntosh David M Director | Exercise or conversion · Stock Options (right-to-buy) | +125,000 | 0 | ||
| 2014-02-27 | CARTHY MARK Director | Grant or award · Stock Options (right to buy) | +20,000 | 20,000 | ||
| 2014-01-12 | Jeong Tae Heum Chief Financial Officer | Grant or award · Stock Option (right to purchase) | +175,000 | 175,000 | ||
| 2014-01-12 | Ahn Chang Ho Director | Grant or award · Stock Option (right to purchase) | +125,000 | 125,000 | ||
| 2014-01-12 | Soni Rakesh President and COO | Grant or award · Stock Option (right to purchase) | +85,000 | 85,000 | ||
| 2014-01-12 | Suzdak Peter David Chief Executive Officer | Grant or award · Stock Option (right to purchase) | +350,000 | 350,000 | ||
| 2013-09-09 | Jeong Tae Heum Chief Financial Officer | Exercise or conversion | +150,000 | $0.24 | $36K | 655,000 |
| 2013-09-09 | Jeong Tae Heum Chief Financial Officer | Shares withheld for taxes | −78,861 | $0.46 | $36K | 576,139 |
| 2013-09-09 | Jeong Tae Heum Chief Financial Officer | Sale | −71,139 | $0.46 | $32K | 505,000 |
| 2013-09-09 | Jeong Tae Heum Chief Financial Officer | Exercise or conversion · Stock Option (right to purchase) | −150,000 | 0 | ||
| 2013-06-11 | Beever Charles Director | Grant or award · Stock Options (right-to-buy) | +60,000 | 60,000 | ||
| 2013-06-11 | McIntosh David M Director | Grant or award · Stock Options (right-to-buy) | +60,000 | 60,000 | ||
| 2013-06-11 | Brandt Peter C. Director | Grant or award · Stock Options (right-to-buy) | +60,000 | 60,000 | ||
| 2013-06-11 | Cheong Kwang Soo Director | Grant or award · Stock Options (right-to-buy) | +60,000 | 60,000 | ||
| 2013-06-11 | Hwang Si Moon Director | Grant or award · Stock Options (right-to-buy) | +60,000 | 60,000 | ||
| 2013-03-01 | Soni Rakesh President and COO | Grant or award · Stock Option (right to purchase) | +50,000 | 50,000 | ||
| 2013-03-01 | Ahn Chang Ho Director | Grant or award · Stock Option (right to purchase) | +250,000 | 250,000 | ||
| 2013-03-01 | Jeong Tae Heum Chief Financial Officer | Grant or award · Stock Option (right to purchase) | +250,000 | 250,000 | ||
| 2013-02-04 | Suzdak Peter David Chief Executive Officer | Grant or award · Stock Option (right to purchase) | +1,200,000 | 1,200,000 |
Page 20 of 22 · 437 trades